Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first‐line, systemic chemotherapy

Abstract

BACKGROUND.Few studies have assessed formally whether treatment outcomes have improved substantially over the years for patients with advanced nonsmall cell lung cancer (NSCLC) enrolled in Phase III trials. The objective of the current investigation was to determine the time trends in outcomes for the patients in those trials.METHODS.The literature was searched to identify trials that addressed the role of chemotherapy regimens in the first‐line setting for the treatment of advanced NSCLC. Trends were tested by using multiple regression analysis.RESULTS.In total, 121 Phase III trials were identified that involved 42,768 patients with 263 chemotherapy arms and 11 best supportive care (BSC) arms, all of which were initiated between 1982 and 2002. Although the number of randomized patients and the proportion of patients with metastatic disease had increased over the years, the number of patients with a poor performance status who were accrued into the trials had decreased. Cisplatin‐based chemotherapy was been investigated most frequently during the period. The multiple regression analysis revealed a significant improvement in median survival and in the median time to disease progression over the years, with annual prolongations of 0.1203 months (3.609 days) and 0.0617 months (1.851 days), respectively (P< .0001 and P < .0130, respectively). In addition, the use of cisplatin and carboplatin was associated significantly with survival prolongation. The median survival for patients who received BSC also increased progressively over the years (P = .0487).CONCLUSIONS.The survival of patients with NSCLC in Phase III trials improved slowly but steadily over time, although the main factors responsible for this improvement remain unknown. Nonetheless, the current results also suggested that novel targets and new agents will be required in the future fight against advanced NSCLC. Cancer 2007 © 2007 American Cancer Society.

Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201

“…Cisplatin-based chemotherapy is the standard of care for advanced non-small-cell lung cancer based on its survival advantage seen in randomized trials and meta-analyses [1][2][3]. On the other hand, nephrotoxicity is the most problematic adverse event [4], and in Japan, the high-volume hydration of 2500-5000 ml has been routinely used in daily clinical practice to avoid renal toxicity.…”

Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer

“…The standard treatment for fit patients with advanced non-small-cell lung cancer (NSCLC) has been platinum-based chemotherapy [1][2][3][4][5]. Since almost all patients with advanced NSCLC will suffer from progression of their disease, one of the ultimate goals of palliative chemotherapy is prolongation of overall survival (OS) as well as improvement of symptoms and quality of life.…”

Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy; hoping for it as a public domain

“…Although cisplatin-based chemotherapy is the standard care for advanced non-small-cell lung cancer (NSCLC) (1)(2)(3), nephrotoxicity is the most problematic adverse event. To avoid it, the classical longterm high-volume hydration (standard hydration; ≥4 l in half a day) has been indicated by the Japanese government.…”